← Back to Clinical Trials
Recruiting NCT07579728

NCT07579728 CALLY Index, Frailty and SOFA-2 for Mortality Prediction in Geriatric ICU Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07579728
Status Recruiting
Phase
Sponsor Istanbul University - Cerrahpasa
Condition Critical Illness
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2026-04-30
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
observational study

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2026-04-30 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to evaluate the prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index, Clinical Frailty Scale (CFS), and SOFA-2 score in predicting mortality among geriatric intensive care unit (ICU) patients. The primary outcome is ICU mortality. Secondary outcomes include 28-day mortality, ICU length of stay, duration of mechanical ventilation, need for renal replacement therapy, and vasopressor requirement. The study also investigates whether the combined use of these parameters improves predictive performance compared to conventional scoring systems such as APACHE II.

Eligibility Criteria

Inclusion Criteria: * Age ≥65 years * Admission to the intensive care unit * Availability of required clinical and laboratory data within the first 24 hours of ICU admission Exclusion Criteria: * Death within the first 24 hours after ICU admission * Missing key clinical or laboratory data * Terminal malignancy receiving palliative care

Contact & Investigator

Central Contact

TUGBA Yesilyurt Dogu, MD

✉ tugbaayesilyurt@gmail.com

📞 +905535150847

Frequently Asked Questions

Who can join the NCT07579728 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07579728 currently recruiting?

Yes, NCT07579728 is actively recruiting participants. Contact the research team at tugbaayesilyurt@gmail.com for enrollment information.

Where is the NCT07579728 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07579728 clinical trial?

NCT07579728 is sponsored by Istanbul University - Cerrahpasa. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology